Max Robotics — Global Service Robot Directory + US Certification

About

Kazuaki Munetomo is a rising figure in urologic oncology, whose work bridges precision diagnostics and cutting-edge interventional technology. His research is centered on two critical frontiers: improving the accuracy of prostate cancer risk stratification and advancing the role of robotic systems in minimally invasive cancer treatment. In a landmark 2020 study, Munetomo tackled the persistent challenge of pathological upgrading after prostatectomy, demonstrating that even when expert pathologists confirm Gleason grade group 1 on biopsy, a significant risk of higher-grade disease remains. This work, cited 13 times, has sharpened clinical decision-making for men considering active surveillance. More recently, his 2023 narrative review on robotic systems in interventional oncology (22 citations) has become a go-to resource, synthesizing the rapid evolution of robotic-assisted ablation, biopsy, and drug delivery. By mapping the current capabilities and limitations of these platforms, Munetomo has provided a roadmap for integrating robotics into routine cancer care. His dual focus on diagnostic precision and technological innovation positions him as a key voice in the shift toward more personalized, less invasive urologic oncology.